Calcilytix Therapeutics, Inc., A Bridgebio Company

This study tests a new medicine called encaleret against usual treatments for people with a rare genetic condition that causes low blood calcium (ADH1). About 67 participants will receive either encaleret or standard care to see if the drug can safely bring calcium levels into a …

This study is for people with autosomal dominant hypocalcemia types 1 or 2 (ADH1/2), rare genetic conditions that cause low calcium levels. Researchers will collect past and future health data from 95 participants to better understand how the disease changes over time. The goal i…